Journal Content Recommendation
01
Optimal timing of influenza vaccination in young children: population based cohort study
In a large quasi-experimental study of children aged 2-5 years vaccinated against influenza in the United States, children who happened to have been born in October were more likely than other children to be vaccinated in October and were least likely to have a diagnosis of influenza in the following flu season. The findings support current recommendations that children be vaccinated in October, preceding a typical influenza season.
https://doi.org/10.1136/bmj-2023-077076
02
Efficacy, reactogenicity, and safety of the adjuvanted recombinant zoster vaccine for the prevention of herpes zoster in Chinese adults ≥ 50 years: A randomized, placebo-controlled trial
In this phase IV observer-blind study conducted between 2021 and 2023 in China, immunocompetent and medically stable ≥ 50-year-olds were randomized 1:1 to receive two RZV or placebo doses, 2 months apart. During a mean follow-up period of 15.2 (±1.1) months, 31 HZ episodes were confirmed (RZV = 0; placebo = 31) for an incidence rate of 0.0 vs 8.2 per 1000 person-years and an overall VE of 100% (95% CI: 89.82-100). The descriptive VE was 100% (85.29-100) for 50-69-year-olds and 100% (60.90-100) for ≥ 70-year-olds. The frequencies of unsolicited AEs, serious AEs, potential immune-mediated diseases, and deaths were similar between both groups. RZV is well tolerated and efficacious in preventing HZ in Chinese ≥ 50-year-olds.
https://doi.org/10.1080/21645515.2024.2351584
03
The impact and cost-effectiveness of pneumococcal immunization strategies for the elderly in England
This study compares vaccination’s impact and cost-effectiveness (CE) with the existing PPV23 vaccine to the new 15- and 20-valent pneumococcal conjugate vaccines (PCV15 and PCV20), targeting adults aged 65 or 75 years old in England. The study showed that both PPV23 and PCV20 were likely to be cost-effective. PCV20 was likely to avert more cases of pneumococcal disease in elderly adults in England than the current PPV23 vaccine, given input assumptions of higher vaccine effectiveness and slower waning for PCV20.
https://doi.org/10.1016/j.vaccine.2024.05.001
Global/National Policy Updates
04
Vaccine Prescription pilots in several cities in China
The Vaccine prescription has recently been piloted in many cities across China as an innovative model to promote adult vaccination. General practitioners and medical doctors are authorized to provide guidance or recommendations to their patients for taking certain types of adult vaccines during the patients’ clinic visits. Local pilots in Shandong, Zhejiang, Tianjin, Chongqing, Wuhan, and Shenzhen effectively improve the adult vaccination rate. (Source: China Preventive Medicine Association)
05
U.S. FDA Approves Merck’s Pneumococcal 21-valent Conjugate Vaccine for Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults
U.S. Food and Drug Administration (FDA) has approved Merck’s Pneumococcal 21-valent Conjugate Vaccine – CAPVAXIVE™ for Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults. CAPVAXIVE is specifically designed to help protect adults against the serotypes that cause most invasive pneumococcal disease (IPD) cases. (Source: www.merck.com)
Content Editor: Tianyi Deng
Page Editor: Ziqi Liu
